Kevin Sutherby Appointed New President of SP Industries

SP Industries, Inc (SP), a leading global provider of fill-finish drug manufacturing solutions, lyophilizers, and laboratory equipment and supplies, has announced the appointment of Kevin Sutherby as its new President.

Kevin Sutherby is a seasoned executive with 15+ years’ experience leading global manufacturing companies, including senior leadership positions at Danaher and Fortive, and most recently as Senior Vice President at Lean Focus LLC, a consulting firm that assists clients in developing and implementing lean solutions.

SP was acquired by industry-leading automation solutions, ATS, in December 2021, to better support the needs of customers throughout the lifecycle of pharmaceutical development and production, as well as in diagnostics, broader life sciences and applied sciences applications.

The implementation of the ATS Business Model (ABM) for disciplined, continuous improvement is a key part of this process, providing problem-solving tools and a template for eliminating waste and driving process improvement. As a driven advocate of embracing lean and continuous improvement methodologies, Mr Sutherby will oversee these processes to enable SP to develop its product range, performance and service for its customers.

“I’m really looking forward to spearheading the next chapter in SP’s success and developing our aseptic and non-aseptic lyophilization portfolio, fill-finish solutions, and life science portfolio within the ATS family of companies,” said Sutherby. “Our focus on customer-driven innovation and lean efficiency will ensure we provide the best solutions for the pharmaceutical, biotech and allied industry sectors.”

Cash Mahesh, Group Executive – Life Sciences Group at parent company ATS said: “We welcome Kevin Sutherby as SP’s new President. His extensive track record of success will empower the business to deliver on our strategic objectives of providing customers with innovative and highest quality end-to-end manufacturing solutions of unrivaled value.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.